secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2026-07-28T11:13:43+00:00
Accession:  0001193125-26-318853
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen Q2 revenue $204M (+13% organic), adj EPS $0.54; raises FY guidance; acquires BioLife
--------------------------------------------------------------------------------

- Q2 revenue $204M, +12% reported, +13% organic; adjusted EPS $0.54 vs $0.37 prior year.
- GAAP operating income flat at $14M; GAAP EPS $0.09 (down from $0.26).
- Full year 2026 guidance raised: organic growth 10.5%-13.5%, adjusted EPS $2.03-$2.09.
- Announced definitive agreement to acquire BioLife Solutions, strengthening cell therapy position.
- Cash and marketable securities $810M at June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312526318853/0001193125-26-318853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312526318853/rgen-20260728.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-318853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer